Title
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.

Permalink
https://escholarship.org/uc/item/6z05n6r1

Journal
Breast cancer research and treatment, 137(1)

ISSN
0167-6806

Authors
Chien, A Jo
Rugo, Hope S

Publication Date
2013

DOI
10.1007/s10549-012-2328-6

Peer reviewed
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

A. Jo Chien · Hope S. Rugo

Abstract  The widespread use of trastuzumab in the past decade has led to a significant and measureable improvement in the survival of patients with human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer, and in many ways has redefined the natural history of this aggressive breast cancer subtype. Historically, survival in patients with HER2-positive disease was dictated by the systemic disease course, and what appears to be the central nervous system (CNS) tropism associated with HER2-amplified tumors was not clinically evident. With improved systemic control and prolonged survival, the incidence of brain metastases has increased, and CNS disease, often in the setting of well-controlled extracranial disease, is proving to be an increasingly important and clinically challenging cause of morbidity and mortality in patients with HER2-positive advanced breast cancer. This review summarizes the known clinical data for the systemic treatment of HER2-positive CNS metastases and includes information about ongoing clinical trials of novel therapies as well as emerging strategies for early detection and prevention.

Keywords  Metastatic breast cancer · Brain metastases · HER2

Introduction

Breast cancer is the second most common solid malignancy that metastasizes to the central nervous system (CNS) [1]. Epidemiologic studies estimate that the incidence of brain metastases (BM) in women with metastatic breast cancer (MBC) is 10–16 % [2, 3], but autopsy reports suggest rates as high as 30 % [2, 4–6]. Morbidity and mortality of patients with breast cancer is generally driven by extent and progression of non-CNS disease. BM often present late in the disease course, long after development of visceral metastases, and thus, historically have not had a significant impact on overall survival (OS). As a result, finding new treatments that target BM has not been prioritized, and nearly all clinical trials have excluded these patients. However, as patients live longer due to advances in human epidermal growth factor receptor-2 (HER2)-targeted and systemic therapy, it appears that the incidence of BM is increasing, often in the setting of well-controlled systemic disease. As a result, controlling or preventing BM in patients with HER2-amplified MBC has become an increasingly important treatment consideration for oncologists.

HER2 overexpression is a well-established risk factor for CNS metastases. Approximately 20–25 % of all breast cancers overexpress HER2, and prior to trastuzumab, HER2-amplified tumors were associated with a more aggressive phenotype and shorter OS than non-amplified tumors [7]. Trastuzumab has redefined the prognosis of HER2-positive disease, and the future for patients with HER2-positive tumors will only improve as promising anti-HER2-targeted agents currently in preclinical and clinical development move into the clinic. Because trastuzumab does not cross the blood–brain barrier (BBB), the CNS serves as a sanctuary for metastatic disease in the setting of...
sustained extracranial control and improved survival. In addition, BM may be associated with debilitating neurological symptoms such as headaches, motor deficits, and seizures [8]. For these reasons, HER2-positive BM may have an increasing impact on the morbidity and mortality of breast cancer patients. Thus, treatments for HER2-positive BM are a growing unmet clinical need deserving of dedicated clinical trials evaluating novel therapeutics and strategies. This review will discuss BM in HER2-amplified MBC, with detailed discussion of current treatment modalities and investigative approaches.

**Incidence of HER2-positive brain metastases**

While there are few data directly comparing the incidence of BM in patients with metastatic HER2-positive versus HER2-negative disease, numerous studies have reported high rates of BM in those with HER2-positive disease [9–15] relative to that described in historical epidemiologic studies where HER2 status was unknown or unavailable [2, 3]. In the registHER study, a prospective observational study of 1,012 patients with newly diagnosed HER2-positive MBC, 37.3% of patients developed BM at a median follow-up of 29 months [10]. Retrospective studies in patients treated with trastuzumab have reported similar rates, generally ranging from 25 to 48% [9, 11–15].

The increased incidence of BM in HER2-positive disease can possibly be attributed to an inherent biologic predisposition. Pestalozzi et al. reviewed data from 9,524 women with early breast cancer from 10 adjuvant clinical trials (1978–1999), none of whom received anthracycline, taxane, or trastuzumab therapy. The 10-year cumulative incidence of CNS as a site of first relapse was higher in patients with HER2-positive versus HER2-negative disease (2.7 vs 1.0%, \( P < 0.01 \)) [16], as was true for the 10-year incidence of CNS recurrence at any time (6.8 vs 3.5%, \( P < 0.01 \)). Although only 41% of patients had HER2 status available (34.3% were HER2-negative and 6.4% were HER2-positive), these data suggest that HER2-amplified tumors may have an inherent biologic tropism for the CNS independent of treatment and other prognostic factors. These findings are consistent with 2 smaller studies [17, 18]; Kallionemi et al. investigated the site of first relapse in 319 patients with trastuzumab-naive breast cancer. HER2-positive tumors metastasized 3 times more often to the lungs, liver, and brain compared with HER2-negative tumors (\( P = 0.0002 \)) [17]. In a Canadian population-based study of 664 patients with early-stage breast cancer, HER2 overexpression was the most significant independent risk factor for future BM [18]. A higher incidence of CNS metastases was observed in HER2-positive than HER2-negative patients (9 vs 1.9%, hazard ratio [HR], 4.23; 95% confidence interval [CI], 1.84–9.74; \( P = 0.0007 \)) in this study (where few patients [8%] received trastuzumab) [18]. Taken together, these observational data suggest that HER2-positive cells may exhibit tissue tropism that cannot be explained by circulatory patterns alone. Based on these observations and others, there is interest in identifying molecular signatures predictive of organ-specific metastases [19, 20]. Such gene signatures could facilitate the design of prevention trials by identifying patients at high risk of developing BM, which would allow for the evaluation of prophylactic measures to potentially inhibit or delay metastasis. In addition, there are efforts to develop a gene signature to predict early versus late development of BM in patients with HER2-positive MBC [21].

It has been hypothesized that the incidence of BM in patients with HER2-positive MBC has increased due to the success of trastuzumab therapy. Because trastuzumab does not cross the BBB due to its large size (185 kDa), the CNS may be largely immune to its antitumor effects. Improved systemic control and OS in the setting of poor CNS coverage allows patients to develop BM that would have previously gone undiagnosed due to rapid extracranial disease progression and death in the pre-trastuzumab era. Although retrospective studies have reported conflicting results [15, 22, 23], several studies have supported this hypothesis, reporting an increased frequency of BM in the setting of controlled extracranial disease in patients who receive trastuzumab as first-line therapy for metastatic disease [12, 13, 24]. For example, Burstein et al. demonstrated that approximately 10% of patients receiving first-line trastuzumab-based regimens had isolated CNS recurrence as a first progression event. Although initial progression at peripheral sites was still more common, patients receiving trastuzumab had a higher incidence of isolated CNS recurrence than those receiving chemotherapy alone [24].

Three large adjuvant trastuzumab trials have reported CNS events. NSABP B-31 and NCCTG N9831 reported a higher incidence of isolated BM as the first site of recurrence in patients randomized to trastuzumab versus control (21 [2.4%] vs 11 [1.3%] in trial B-31 and 12 [1.5%] vs 4 [0.5%] in trial N9831) [25], while in the HERA trial, there was no difference in CNS metastases between the 2 treatment arms (1.5 vs 1.3%) [26]. NSABP B-31 was the only trial to report cumulative incidence of BM (first or subsequent) and showed no significant difference between groups (28 [3.2%] vs 35 [4.0%], respectively; \( P = 0.35 \)) [25]. These data suggest that imbalances in first events are due to improved extracranial systemic control with trastuzumab. Two meta-analyses of the 3 adjuvant trials (including >6,000 patients) reported an increased risk of BM among patients treated with trastuzumab [27, 28]. Similarly, another meta-analysis of >9,000 patients...
reported an increased risk of BM as the first site of disease recurrence among HER2-positive breast cancer patients treated with adjuvant trastuzumab [29].

**Prognosis of HER2-positive brain metastases**

Survival of patients with CNS metastases is poor, with 1- and 2-year survival rates of 20 and <2 %, respectively [30]. In the pre-trastuzumab era, evidence suggested shorter OS in patients with HER2-positive than HER2-negative BM [31]; however, several retrospective studies and 1 prospective observational study reported longer OS and survival after diagnosis of BM in patients with trastuzumab-treated HER2-positive disease versus HER2-negative or HER2-positive patients not receiving trastuzumab. In trastuzumab-treated patients, median survival from diagnosis of CNS metastases has varied across studies, ranging from 12 to 25 months [12, 15, 22, 32–35].

In a Korean single-center review of patients receiving palliative chemotherapy for HER2-positive MBC, systemic extracranial disease control and lack of progression of extracranial disease for ≥12 months after diagnosis of BM were among the independent prognostic factors for death from CNS disease [15]. Proportions of deaths from BM and extracranial systemic disease in the pre-trastuzumab era were 45.7 versus 37.1 %, respectively (n = 35), and 59.5 versus 11.9 % in trastuzumab-treated patients (n = 42).

**Current and emerging systemic treatments for HER2-positive brain metastases**

Historically, BM trials have included patients with various solid tumors. There are few trials testing novel therapies specifically in breast cancer BM, and even fewer solely in patients with HER2-positive disease (Table 1). Other challenges include non-uniform standards of response assessment and difficulty in accessing tissue for definitive diagnosis. Local therapy consisting of surgery followed by whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), or WBRT alone remains the standard of care for initial management of BM due to MBC as well as BM arising from many other primary tumor sites; a full discussion of local therapy control is beyond the scope of this review. The remainder of the review will focus on existing and emerging systemic therapies for HER2-positive BM.

**Chemotherapy**

Use of standard cytotoxic chemotherapy for the treatment of BM is limited by poor drug penetration across an intact BBB, drug efflux mediated by high expression of P-glycoprotein (PgP) in brain capillary endothelial cells, and development of BM late in the disease course when the tumor is resistant to multiple lines of chemotherapy [8, 36–39]. Despite this, several agents have demonstrated CNS activity, likely as a result of increased vessel permeability associated with tumor metastases and radiation effects [40, 41]. Evidence suggests both size of metastases [42] and breast cancer subtype [43] impact the degree of BBB disruption. An ongoing trial is evaluating the penetrability of various chemotherapeutic and targeted agents, comparing intratumoral and blood drug concentrations in patients with ≥1 resectable breast cancer BM who receive 1 dose of chemotherapy or targeted therapy (trastuzumab or lapatinib) prior to surgery (NCT00795678).

In recent years, a limited number of newer chemotherapeutic agents have demonstrated activity in prospective studies of MBC-related BM (Table 2). In general, the most promising agents for CNS disease are agents that are active against breast cancer, regardless of BBB permeability. For example, temozolomide, although relatively permeable, is not very active against breast cancer and has shown limited activity in the CNS [44–47]. In contrast, cisplatin has shown clinical activity with MBC-associated BM both as a single agent and in combination with other chemotherapies and WBRT [48–51]. Similarly, there are provocative retrospective data with capecitabine, an agent with well-established efficacy in breast cancer, which has been proposed to cross the BBB via the human concentrative nucleoside transporter (hCNT) [52, 53]. A phase II trial is evaluating capecitabine monotherapy in patients with MBC and CNS progression after WBRT alone or with SRS and no prior systemic therapy for BM (NCT01077726). Phase II trials are also evaluating WBRT ± capecitabine in breast cancer-associated BM (NCT00977379/XERAD, NCT00570908).

**Anti-HER2 therapies**

**Trastuzumab**

Although penetration of trastuzumab across an intact BBB is limited, it may be enhanced when the BBB is compromised by radiation, BM, or meningeal carcinomatosis [54, 55]. There are no clinical studies directly examining the impact of trastuzumab on BM; however, retrospective studies suggest improved outcomes in patients developing BM on trastuzumab, who then continue trastuzumab after radiation [34, 35]. Although this benefit is likely due to better systemic control, 1 study reported a trend toward longer time to CNS progression, suggesting a possible direct CNS effect, although this remains controversial [34].

It is unknown whether trastuzumab functions as a radiosensitizer. Trastuzumab has been shown to enhance
radiation-induced apoptosis of breast cancer cells in a HER2 level-dependent manner in preclinical studies [56], but clinical studies are lacking. One small single-arm study of concurrent trastuzumab and WBRT demonstrated safety and activity with a radiographic response rate (RR) of 74% [57]. Randomized studies of WBRT versus concurrent trastuzumab plus WBRT have not been performed. However, radiation may improve the ability of trastuzumab to cross the BBB. In a study of 6 patients with HER2-positive BM undergoing treatment with trastuzumab and WBRT, the ratio of trastuzumab concentrations in serum and cerebral spinal fluid (CSF) was 420:1 prior to radiation and 76:1 after radiation [55].

It is possible that the efficacy of trastuzumab against intracerebral metastases could be increased with improved delivery across the BBB. This is supported by data demonstrating improved survival with trastuzumab intracerebral microinfusion (ICM) in HER2-positive breast cancer xenografts, without evidence of clinical or histological toxicity, compared to intraperitoneal trastuzumab or ICM with saline [58]. Several case reports, primarily in HER2-positive leptomeningeal disease, have suggested intrathecal trastuzumab demonstrated clinical benefit and was generally well tolerated [59–65]; however, this remains experimental. A phase I/II trial of intrathecal trastuzumab in patients with HER2-positive leptomeningeal disease is ongoing (NCT01325207).

**Table 1** Planned or active clinical trials for patients with HER2-positive MBC with brain metastases

| Trial | Planned accrual | Population | Treatment | Primary endpoint(s) | Status |
|-------|----------------|------------|-----------|---------------------|--------|
| Trastuzumab Phase I/II (NCT00397501) | 78 | HER2-positive or HER2-negative MBC with CNS or brain metastases | Trastuzumab, methotrexate, and carboplatin with osmotic BBB disruption | OS | Not yet recruiting |
| Phase II (NCT01363986) | 66 | HER2-positive breast cancer and ≥1 measurable brain metastasis | Trastuzumab plus WBRT | Brain RR | Recruiting |
| Afatinib Phase II [100] (NCT01441596; LUX-breast 3) | 120 | HER2-positive MBC with CNS metastasis (≥1 measurable brain lesion) | Afatinib, afatinib/vinorelbine, or investigator’s choice of therapy | Benefit at 12 weeks⁴ | Recruiting |
| Lapatinib Phase I (NCT00614978; LAPTEM) | 18 | HER2-positive MBC with recurrent or progressive brain metastases after surgery, WBRT, or SRS (or unsuitable for these standard treatments) | Lapatinib plus temozolomide | MTD and DLT | Ongoing, not recruiting |
| Phase I (NCT00470847) | 39 | HER2-positive MBC, ≥1 parenchymal brain lesion, and CNS progression | Lapatinib plus WBRT | MTD and feasibility | Ongoing, not recruiting |
| Neratinib Phase II (NCT01494662) | 45 | HER2-positive MBC, ≥1 parenchymal brain lesion, and any number and type of prior therapy (other than neratinib) allowed | Neratinib (progressive brain metastases) or neratinib/surgical resection (if eligible for craniotomy) | Recruiting |
| Everolimus Phase II (NCT01305941) | 35 | HER2-positive breast cancer with brain metastases (≥1 measurable brain lesion), and any number and type of prior therapy (other than mTOR inhibitors or Navelbine) allowed | Everolimus plus trastuzumab and vinorelbine | Intracranial RRb | Recruiting |

**BBB** blood–brain barrier, **CNS** central nervous system, **DLT** dose-limiting toxicity, **HER2** human epidermal growth factor receptor-2, **MBC** metastatic breast cancer, **MTD** maximum tolerated dose, **OS** overall survival, **RR** response rate, **SRS** stereotactic radiosurgery, **WBRT** whole-brain radiotherapy

Includes trials indexed on clinicaltrials.gov for which results are forthcoming, as of October 2012

⁴ Benefit described as absence of CNS or extra-CNS progression
⁵ Modified RECIST criteria

**Lapatinib**

Lapatinib is an oral, reversible, small molecule tyrosine kinase inhibitor (TKI) targeting HER2 and EGFR/HER1 [66].
Lapatinib is approved in combination with capecitabine in patients with HER2-positive trastuzumab-treated MBC [67], as well as with letrozole in patients with hormone receptor- and HER2-positive advanced disease [68]. Although lapatinib is a small, lipophilic molecule (581 Da) that can cross the BBB, it is a substrate of PgP, breast cancer resistance protein 1 (BCRP1), and other drug efflux proteins. Preclinical studies of PgP and BCRP1 knockout mice treated with lapatinib demonstrate increased brain:plasma lapatinib concentrations (1.2–1.7) compared with wild-type mice (0.03–0.04) [69].

| Agent(s) | Patient population/setting | N Total | N BC | N HER2+ | Efficacy |
|----------|-----------------------------|---------|------|---------|----------|
| Cisplatin | Previously untreated brain metastases from solid tumors | 34 | 8 | NR | RR (brain) = 42 % (14/33) among all tumor types; RR (brain) = 87.5 % (7/8, 4 CRs and 3 PRs) in BC |
| Cisplatin + etoposide | Surgically ineligible brain metastases from solid tumors | 14 | 4 | NR | RR (brain) = 14 % (2/14; 1 PR in BC) |
| Cisplatin + etoposide | First-line for brain metastases from BC, NSCLC, or melanoma | 116 | 56 | NR | RR (brain) = 38 % (21/56, 7 CRs and 14 PRs) in BC; TTP (brain) = 17 weeks in BC; Median OS = 31 weeks in BC |
| Cisplatin + vinorelbine + WBRT | Previously untreated brain metastases from BC | 25 | 25 | 7 | RR (brain) = 76 % (19/25, 3 CRs and 16 PRs); RR (systemic) = 44 % (1 CR, 10 PRs); Median PFS (brain) = 5.2 months; Median PFS (systemic) = 3.7 months; Median OS = 6.5 months |
| Temozolomide + cisplatin | Brain metastases from solid tumors | 32 | 15 | NR | RR (brain) = 6/15 in BC; Median TTP (systemic) = 2.9 months among all tumor types; Median OS = 5.5 months among all tumor types |
| Temozolomide + WBRT | Brain metastases from solid tumors | 33 | 7 | NR | RR (brain) = 57.6 % after 6 cycles among all tumor types; RR (brain) = 2/7 in BC; Median RFS = 11 months among all tumor types; Median OS = 12 months among all tumor types |
| Temozolomide (protracted low-dose) + WBRT | Brain metastases from BC or NSCLC | 27 | 12 | NR | RR (brain) = 48.1 % among all tumor types; RR (brain) = 7/12 (1 CR, 6 PRs) in BC; Median TTP (brain) = 6 months (95 % CI, 5.1–6.8) among all tumor types; Median OS = 8.8 months (95 % CI, 6.8–8.9) among all tumor types |
| Temozolomide (dose dense) | Brain metastases from BC, NSCLC, or melanoma | 157 | 51 | NR | RR (brain) = 6 % (10/157, 1 CR and 9 PRs) among all tumor types; RR (brain) = 4 % (2/51, 2 PRs) in BC; Median OS = not reached in BC |
| Capecitabine + lapatinib | HER2-positive brain metastasis from BC | 43 | 43 | 43 | RR (brain) = 67 % in BC; Median TTP (brain) = 5.5 months in BC |
| Capecitabine + lapatinib | HER2-positive brain metastasis from BC | 13 | 13 | 13 | RR (brain) = 38 % (5/13; all 5 PRs) in BC |

BC breast cancer, CI confidence interval, CR complete response, HER2 human epidermal growth factor receptor-2, NSCLC non-small cell lung cancer, NR not reported, OS overall survival, PFS progression-free survival, PR partial response, RFS relapse-free survival, RR response rate (CR + PR), TTP time to progression, WBRT whole-brain radiotherapy
These data may, at least in part, explain the modest CNS clinical activity seen with lapatinib.

A pilot phase II trial evaluated lapatinib monotherapy in 39 patients with HER2-positive BM that developed during trastuzumab therapy [70]. This study reported a 2.6 % RR in the CNS per RECIST criteria, which did not meet the prespecified cut off for further investigation. An exploratory analysis suggested that volume change may be a more appropriate primary efficacy endpoint in trials of CNS disease. A multicenter phase II trial evaluated lapatinib monotherapy in 242 patients with HER2-positive BM progressing after trastuzumab and radiation [71]. Enrollment completed in 12 months, reflecting the demand for clinical trials in this population. The primary endpoint was ≥50 % volumetric reduction in the sum of all lesions. Volumetric analysis in 200 patients demonstrated ≥50 % reduction in 6 % of patients and ≥20 % reduction in 21 %. Volumetric reduction was associated with improved progression-free survival; diarrhea (13 %) was the only grade 3 to 4 toxicity affecting ≥5 % of patients. A phase I study is exploring lapatinib plus WBRT in patients with BM from HER2-overexpressing breast cancer (NCT00470847).

Fifty patients entered an extension phase testing the combination of lapatinib plus capecitabine at the time of progression [71]. A ≥50 and ≥20 % volume reduction in CNS lesions was observed in 20 and 40 % of patients, respectively. The clinical significance of such a response is not clear; however, an exploratory analysis showed that improvement in time to progression (TTP) was observed in patients with ≥10 % volumetric reduction compared with those with lesser or no reduction (P = 0.04) [70]. In the United Kingdom expanded access program of lapatinib and capecitabine for HER2-positive MBC, 34 patients had CNS disease, the majority of whom had received prior radiation (94 %). CNS response by RECIST criteria was seen in 21 % of patients (including 1 complete response [CR]) [72]. The Korean expanded access program of lapatinib and capecitabine for HER2-positive MBC [73] and an Italian analysis (2 centers) comparing lapatinib and capecitabine against trastuzumab-based regimens in patients with BM and prior trastuzumab therapy [74] reported clinical benefit as well. Results from LANDSCAPE, a phase II study to determine if patients with HER2-positive MBC-associated BM who receive lapatinib plus capecitabine can avoid or delay WBRT, support a high CNS RR of 67 % among 43 evaluable patients, with median TTP of 5.5 months and median time to WBRT of 8.3 months [75]. It is important to note that the individual contributions of lapatinib versus capecitabine versus the combination are unknown, as many of these patients had not received prior capecitabine, which appears to have independent CNS activity. A randomized phase II study compared lapatinib plus capecitabine to lapatinib plus topotecan for patients with HER2-positive breast cancer BM progressing after trastuzumab and radiotherapy. Although the study was stopped before full enrollment, CNS activity was noted for lapatinib/capecitabine and not for lapatinib/topotecan [76].

Whether lapatinib monotherapy can decrease the risk of developing CNS metastases is unknown. Clinical data are limited to an exploratory analysis of the phase III registry trial of lapatinib and capecitabine versus capecitabine alone in 399 patients with HER2-positive MBC previously treated with trastuzumab. Significantly fewer patients had symptomatic CNS progression as the first progression event with the combination versus monotherapy (2 vs 6 %; P = 0.045) [77], but the overall incidence of CNS metastases was not reported [78].

Lapatinib pharmacokinetics data in the CNS are lacking, largely because lapatinib is highly insoluble and cannot be measured in the CSF. Preclinical studies have demonstrated that higher doses of lapatinib can lead to higher concentrations in brain tissue [69]. This is supported by clinical reports showing tolerability, activity, and increased CSF penetration with high-dose HER-family small molecule TKIs in lung cancer patients [79, 80], suggesting that CNS activity of small molecule HER2-targeted therapies may be optimized through alternate dosing strategies.

Neratinib

Neratinib, an irreversible oral TKI against HER1/EGFR, HER2, and HER4, has demonstrated activity in trastuzumab-naive and trastuzumab-refractory disease [81–83], but clinical trials to date have excluded patients with active CNS metastases. A phase II open-label, single-arm study of neratinib in patients with HER2-overexpressing breast cancer with BM is currently recruiting (NCT01494662). The primary endpoint is response based on volumetric assessment. Neratinib concentrations will be measured in the plasma, as well as tumor tissue and CSF in patients undergoing craniotomy. Cognitive function will also be assessed.

Afatinib

Afatinib (BIBW 2992), an irreversible ErbB family inhibitor of HER1/EGFR, HER2 [84], and HER4 [85], has shown preliminary activity in a phase II study in HER2-positive MBC after failure of trastuzumab, with 4 partial responses (PRs) and 15 patients with stable disease (SD) among 35 evaluable patients [86]. Early clinical data also suggest afatinib may be active against BM, based on a phase I study during which a patient with NSCLC experienced PR of BM with continued afatinib therapy [87]. A phase II study (NCT01441596) comparing the efficacy
and safety of afatinib alone, afatinib in combination with vinorelbine, and the investigator’s choice of chemotherapeutic regimen in patients with HER2-overexpressing MBC with BM who have had prior trastuzumab and/or lapatinib therapy is currently recruiting.

**Pertuzumab**

Pertuzumab (Perjeta™), a HER2-targeted monoclonal antibody, was recently approved in combination with trastuzumab and docetaxel for the treatment of chemotherapy-naive HER2-positive MBC [88]. Currently, there are no data regarding the efficacy of pertuzumab in treating BM; it is expected that the activity will be similar to trastuzumab in terms of its limited ability to cross the BBB.

**Novel cytotoxic agents**

Several novel cytotoxic agents with the ability to cross the BBB have recently been evaluated in patients with BM arising from several solid tumors, including breast cancer. A single-arm, phase II study evaluating the efficacy and safety of sagopilone, an epothilone B analogue and tubulin-stabilizing agent, in 15 breast cancer patients with BM reported that 2 patients (1 with HER2-positive disease) achieved a CNS PR (overall CNS RR, 13.3 %), with a median progression-free survival and OS of 1.4 and 5.3 months, respectively [90]. In a phase I, dose-escalation study, GYN1005, a novel peptide-drug conjugate of paclitaxel covalently linked to angiopep-2, was reported to shrink brain lesions arising from several primary tumor sites, including the breast [91].

**Antiangiogenic therapy**

Preclinical and clinical data suggest that the aggressive phenotype of HER2-overexpressing breast cancers may be mediated, in part, by upregulation of vascular endothelial growth factor (VEGF), and provide rationale for combining anti-HER2 and anti-VEGF therapies for the treatment of HER2-overexpressing breast cancers [92–94]. Limited data are available utilizing antiangiogenic therapy for BM, but a case series of 4 patients with CNS metastases (n = 3 brain; n = 1 meningeal) from MBC described 1 CR and 3 PRs with bevacizumab plus paclitaxel [95]. One of the patients who achieved PR of a cerebellar lesion had HER2-positive disease previously treated with chemotherapy/trastuzumab and lapatinib/capecitabine. A phase II trial is evaluating bevacizumab plus carboplatin in patients with progressive BM from MBC (not HER2-positive specific), allowing prior trastuzumab therapy (NCT01004172). Preliminary results from another phase II trial evaluating bevacizumab plus etoposide and cisplatin in breast cancer patients with progressive BM (not HER2-positive specific) after WBRT showed that 9 out of 12 evaluable patients (75 %) achieved a CNS objective response (defined as a ≥50 % reduction in the volumetric sum of all measureable CNS lesions) with 6 patients (50 %) achieving ≥80 % volumetric reduction [96].

**Early detection and prevention**

Given the increased incidence of BM in HER2-positive MBC, early detection strategies may offer improved outcomes. At this time, there are no data to support early screening for occult BM. In a study of 155 asymptomatic patients with MBC undergoing brain MRI screening for clinical trial participation, 15 % of patients had occult CNS metastases [97]. The authors found no difference in OS between patients with occult metastases detected by screening and patients with symptomatic CNS metastases from a separate cohort. HER2-overexpression was predictive of CNS involvement in multivariate analysis [97]. In a more recent study, 80 patients with HER2-overexpressing MBC without neurologic symptoms were screened for occult BM every 3 months [98]. Occult metastases were detected in 36 % of patients, 90 % of whom received WBRT. Compared with a separate cohort receiving WBRT for symptomatic BM, use of early WBRT decreased the rate of death from BM (16 vs 48 %; P = 0.009) but had no impact on OS (53 vs 51 months, P = 0.944).

An ongoing randomized trial is being conducted in women with HER2-positive MBC without neurologic symptoms evaluating gadolinium-enhanced MRI of the brain once every 4 months versus every 12 months for early detection of CNS metastases (NCT00398437); OS is the primary endpoint. Prophylactic cranial irradiation (PCI) with WBRT, which has shown benefit in certain malignancies, does not have an established role in breast cancer [99]. However, a phase I trial of PCI in patients with HER2-positive MBC was recently completed (NCT00916877), and a randomized phase III trial is evaluating a 6-week course of taxane/trastuzumab alone or with concurrent PCI (NCT00639366). Lastly, a phase II trial evaluating temozolomide for the prevention of BM in patients...
Conflict of interest

The field of HER2-positive breast cancer is among the most active areas of breast cancer research today. As a result, numerous novel HER2-targeted agents are in various phases of clinical development, many of which have shown promising clinical activity with regard to systemic control. Thus, CNS metastases will likely be an increasingly common occurrence for patients with HER2-positive MBC, leading to the need to find effective strategies for the treatment, management, and prevention of CNS disease. The future for patients with HER2-positive breast cancer is bright; however, clinical and research efforts must focus on ways to target and penetrate the BBB. This will require dedicated clinical trials for patients with active CNS disease, including trials of novel drugs, alternate modes of treatment delivery, and multimodality therapies.

Acknowledgments This work was written by the authors and supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). Editorial assistance was provided by Laurie Orloski, PharmD, of MedErgy, which was contracted by BIPI for these services. The authors were fully responsible for all content and editorial decisions and received no compensation related to the development of the manuscript.

Conflict of interest The University of California has received funding from Genentech/Roche and GlaxoSmithKline to support research led by Dr Rugo. Dr Chien has no potential conflicts to disclose.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. DiStefano A, Yong YY, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44:1913–1918
2. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52:2349–2354
3. Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81:1109–1112
4. Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23:175–180
5. Hagemeister FB Jr, Buzdar AU, Luna MA, Blumenschein GR (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46:162–167
6. Cho SY, Choi HY (1980) Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. Am J Clin Pathol 73:232–234
7. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udoe J, Ulrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
8. Cheng X, Hung MC (2007) Breast cancer brain metastases. Cancer Metastasis Rev 26:635–643
9. Altaha R, Crowell E, Hobbs G, Higa G, Abraham J (2005) Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 103:442–443
10. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LJ, Bramermer MG, Shing M, Yool MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17:4834–4843
11. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O’Brien ME, Smith IE (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201
12. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977
13. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643
14. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219–225
15. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH (2009) Trastuzumab treatment improves brain metastasis outcome through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100:894–900
16. Pestalozzi BC, Zahiri D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fee MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944
17. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650–655
18. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663
19. Landemaine T, Jackson A, Bellobaghe C, Rucci N, Sin S, Abdulkarim B, Aoudinet A, Guinébretière JM, Ricevuto E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944
20. Minn AJ, Kang Y, Serhanova I, Gupta GP, Giri DD, Dabbourov M, Ponomarev V, Gerald WL, Blasberg R, Massague J (2005)
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115:44–55

Duchnowska R, Jassem J, Goswami CP, Gokem-Polar Y, Thorat MA, Flores N, Hua E, Woditschka S, Palmieri D, Steinberg S, Biernat W, Sosinak-Mielcarek K, Szostkiewicz B, Czartoryska-Arlukowicz B, Radecka B, Tomasevic Z, Sledge GW, Steeg PS, Badve SS, Polish Brain Metastasis Consortium, Military Institute of Medicine WP, Medical University of Gdańsk GP, Indiana University School of Medicine II, Wolfson Institute of Preventive Medicine LUKK, National Cancer Institute BM, National Institutes of Health BM, Bialystok Oncology Center BP, Opole Oncological Center OP, Institute for Oncology and Radiology BSA, Indiana University Simon Cancer Center II (2012) 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. J Clin Oncol 30:Abstract 505

Lai R, Dang CT, Malkin MG, Abrey LE (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816

Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK (2003) Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4:114–119

Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorshem HE, Graas JA, Huang S, Palmieri D, Steeg PS, Smith QR (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in mouse brain metastases of breast cancer. Clin Cancer Res 16:5664–5678

Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617

Deeken JF, Loscher W (2007) The blood–brain barrier and therapy: implications for timing of chemotherapy? (Review). Neuro Oncol 9:683–688

Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21:107–112

Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fijiwara Y (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116:302–308

Christodoulou C, Bafaloukos D, Linardou H, Aravanitos G, Balmias A, Carina M, Klouvas G, Skarlos D (2005) Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 71:61–65

Kouvaris JR, Miliadou A, Kouloulis VE, Kolokouris D, Balafouta MJ, Papacharalampus XN, Vilhos LJ (2007) Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 30:361–366

Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, Guarasi R, Vincenzi B, Caraglia M, del Prete S (2008) Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 113:2524–2531
47. Siena S, Crino L, Danova M, Del PS, Caciniu S, Salvagni S, Sgiaiott O, Vitali M, Bajetta E (2010) Dose-dense temozolo- 
mide regimen for the treatment of brain metastases from mel-
oma, breast cancer, or lung cancer not amenable to surgery 
or radiosurgery: a multicenter phase II study. Ann Oncol 21:655–661

48. Kolaric K, Roth A, Jelicic I, Matkovic A (1982) Phase II clinical 
trial of cis dichlorodiammine platinum (Cis DDP) in metastatic 
brain tumors. J Cancer Res Clin Oncol 104:287–293

49. Vinolas N, Graus F, Mellado B, Caralt L, Estape J (1997) Phase 
II trial of cisplatin and etoposide in patients with brain metastases 
of solid tumors. J Neurooncol 35:145–148

50. Franciosi V, Cocconi G, Michiara M, Di CE, Fosser V, Tonato 
M, Carlpi P, Boni C, Di SS (1999) Front-line chemotherapy 
with cisplatin and etoposide for patients with brain meta-
tases from breast carcinoma, nonsmall cell lung carcinoma, 
or malignant melanoma: a prospective study. Cancer 85: 1599–1605

51. Cassier PA, Ray-Coquard I, Sunyach MP, Lancrey L, Guastalla 
JP, Ferralay C, Gomez F, Cure H, Lortholary A, Claude L, Blay 
JY, Bachelot T (2008) A phase 2 trial of whole-brain radio-
therapy combined with intravenous chemotherapy in patients 
with brain metastases from breast cancer. Cancer 113:2532–2538

52. Ekenel M, Hormigo AM, Peak S, DeAngelis LM, Abrey LE 
(2007) Capecitabine therapy of central nervous system meta-
tases from breast cancer. J Neurooncol 85:223–227

53. Chargari C, Kirova YM, Dieras V, Castro PP, Campana F, Cottu 
PH, Pierga J, Fourquet A (2009) Concurrent capectabine and 
whole-brain radiotherapy for treatment of brain metastases in 
breast cancer patients. J Neurooncol 93:379–384

54. Dijkers EC, Oude Munnik HK, Kosterink JG, Brouwer AH, 
Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de 
Hooge MN, de Vries EG (2010) Biodistribution of 89Zr-trast-
uzumab and PET imaging of HER-2-positive lesions in patients 
with metastatic breast cancer. Clin Pharmacol Ther 87:586–592

55. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, 
Heinemann V (2007) Ratio of trastuzumab levels in serum and 
cerebrospinal fluid is altered in HER2-positive breast cancer 
patients with brain metastases and impairment of blood-brain 
barrier. Anticancer Drugs 18:23–28

56. Liang K, Lu Y, Jin W, Ang KK, Milas L, Ang KK, Jin W, Ang KK, 
Cottu PH, Pierga J, Fourquet A (2009) Concurrent capectabine and 
whole-brain radiotherapy for treatment of brain metastases in 
breast cancer patients. J Neurooncol 85:223–227

57. Chargari C, Idrissi HR, Pierga JY, Bollet MA, Dieras V, Cam-
pana F, Cottu P, Fourquet A, Kirova YM (2011) Preliminary 
results of whole brain radiotherapy with concurrent trastuzumab 
and PET imaging of HER-2-positive lesions in patients 
with metastatic breast cancer. Clin Pharmacol Ther 87:586–592

58. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, 
Harris GF, Bullitt E, Van den Abbeele AD, Henson JW, Li X, 
Laubman LR, Feldman K, Caralt L, Estape J (2001) Use of intrathecal trastuzumab (HerceptinTM) for treatment of 
melanoma, breast cancer, or lung cancer not amenable to surgery 
or radiosurgery: a multicenter phase II study. Ann Oncol 21:655–661

59. Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, 
Aristei C, Floridi P (2009) Extended survival of a HER-2-
positive metastatic breast cancer patient with brain metastases 
also treated with intrathecal trastuzumab. Cancer Chemother 
Pharmacol 63:1157–1159

60. Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab for leptomeningeval meta-
tases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978–1980

61. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) 
High-dose intrathecal trastuzumab for leptomeningeval meta-
tases from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778–780

62. Oliveira M, Braga S, Passos-Coelho IL, Fonseca R, Oliveira J 
(2011) Complete response in HER2+ leptomeningeval carcinom-
atosis from breast cancer with intrathecal trastuzumab. Breast 
Cancer Res Treat 127:841–844

63. Platini C, Long J, Walter S (2006) Meningeal carcinomatosis 
from breast cancer treated with intrathecal trastuzumab. Lancet 
Oncol 7:1373–1377

64. Stemmler HJ, Schmitt M, Harbeck N, Laubman LR, Shehata M, 
Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, 
Cameron D (2006) Lapatinib plus capecitabine for HER-2-positive 
advanced breast cancer. N Engl J Med 355:2733–2743

65. Johnston S, Pippen J Jr, Pivot X, Lichinister M, Sadeghi S, 
Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, 
Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, 
Pegram M (2009) Lapatinib combined with letrozole versus 
letrozole and placebo as first-line therapy for postmenopausal 
hermone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

66. Burris HA III, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, 
O’Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris 
(2005) Phase I safety, pharmacokinetics, and clinical activity 
study of lapatinib (GW572016), a reversible dual inhibitor of 
epidermal growth factor receptor tyrosine kinases, in heavily 
treated patients with metastatic carcinomas. J Clin Oncol 23:5305–5313

67. Yeger CE, Forster J, Linquist D, Chan S, Romieu CG, Pienkowski T, 
Jagiello-Gruszfeld A, Crow J, Chan A, Kaufman B, Sklaros D, 
Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, 
Cameron D (2006) Lapatinib plus capecitabine for HER-2-positive 
advanced breast cancer. N Engl J Med 355:2733–2743

68. Johnston S, Pippen J Jr, Pivot X, Lichinister M, Sadeghi S, 
Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, 
Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, 
Pegram M (2009) Lapatinib combined with letrozole versus 
letrozole and placebo as first-line therapy for postmenopausal 
hermone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

69. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, 
Harris GF, Bullitt E, Van den Abbeele AD, Henson JW, Li X, 
Laubman LR, Shehata M, Kasparian E, Kirsch DG, Crawford A, 
Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain 
metastases in patients with human epidermal growth factor 
receptor-2 positive breast cancer. J Clin Oncol 26:1993–1999

70. Lin NU, Pippen J Jr, Pivot X, Lichinister M, Sadeghi S, 
Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, 
Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, 
Pegram M (2009) Lapatinib combined with letrozole versus 
letrozole and placebo as first-line therapy for postmenopausal 
hermone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

71. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, 
Stemmler HJ, Schmitt M, Harbeck N, Laubman LR, Shehata M, 
Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, 
Cameron D (2006) Lapatinib plus capecitabine for HER-2-positive 
advanced breast cancer. N Engl J Med 355:2733–2743

72. Johnston S, Pippen J Jr, Pivot X, Lichinister M, Sadeghi S, 
Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, 
Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, 
Pegram M (2009) Lapatinib combined with letrozole versus 
letrozole and placebo as first-line therapy for postmenopausal 
hermone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

73. Ro J, Park S, Kim SB, Kim TY, Im YH, Rha SY, Chung JS, 
Moon H, Santillana S (2012) Clinical outcomes of HER2-
positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer 12:322

74. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crino L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22:625–630

75. Bachelot TD, Romieu G, Campone M, Dieras V, Crozet C, Roche HH, Jimenez M, Le Rhun E, Pierga J, Goncalves A, Leheurteur M, Domont J, Gutiérrez M, Cure H, Ferrariero J, Labbe C (2011) LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 29;Abstract 509

76. Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski L, Lane SR, Zembrycki D, Rubin SD, Winer EP (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105:613–620

77. Cameron D, Casey M, Press M, Linderquist D, Pienkowski T, Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski L, Lane SR, Zembrycki D, Rubin SD, Winer EP (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105:613–620

78. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky V, Raats JI, Skarlos D, Newstast B, Rooychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543

79. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from ependymal growth factor receptor mutant lung cancer. J Neurooncol 99:283–286

80. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE (2006) Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB Family Blocker. J Pharmacol Exp Ther 343:342–350

81. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520

82. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Randane A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharuk C, Badwe R (2010) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:3965–3972

83. Konecný GE, Meng YG, Untch M, Wang HJ, Baurleinfeld I, Johnell M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamom DJ, Pegram MD (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Breast Cancer 11:376–383

84. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J (2012) Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopoiet-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11:308–316

85. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Genentech (2012) FDA Grants Genentech’s pertuzumab priority review for previously untreated HER2-positive metastatic breast cancer. February 7, 2012. http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=13847. Accessed 7 Feb 2012

86. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crino L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22:625–630

87. Chow L, Gupta S, Hershman D, Jiang Z, Epstein R, Bondarenko I, Coughlin C, Freymann A, Zhao Y, Abbas R, Awada A (2009) Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in ErbB2+ metastatic breast cancer. Presented at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9–13, 2009, San Antonio, TX, Abstract 5081

88. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80–85

89. Afinitor® (2009) Afinitor® (everolimus) tablets for oral administration [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ

90. Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU (2011) A phase II study of sagopilone (ZK 291947; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 11:376–383

91. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J (2012) Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopoiet-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11:308–316

92. Solca F, Dahl G, Zeoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksema E, Adolf GR (2012) Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB Family Blocker. J Pharmacol Exp Ther 343:342–350

93. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Hepp H, Slamom DJ, Pegram MD (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10:1706–1716

94. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA (2000) Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19:3460–3469

95. Labidi SI, Bachelot T, RAult-Couquard I, Molabah K, Treilleux I, Fayette J, Favier B, Galy G, Blay J, Guastalla JP (2009) Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 9:118–121

96. Lu Y-S, Chen W-W, Lin C-H, Tseng L-M, Yeh D-C, Wu P-F, Chen B-B, Chao T-C, Tsai Y-F, Huang S-M, Shih TT-F, Cheng A-F (2012) Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy:
results of the first stage of a multicenter phase II study. J Clin Oncol 30:Abstract 1079

97. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, Sledge GW Jr (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14:1072–1077

98. Niwinska A, Tacikowska M, Murawska M (2010) The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 77:1134–1139

99. Huang F, Alrefae M, Langleben A, Roberge D (2009) Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int J Radiat Oncol Biol Phys 73:752–758

100. Joensuu H, Kaci MO (2012) LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator’s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy. J Clin Oncol 30: Abstract TPS647